nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-7EC5FA7E·Framework v5.10·Pipeline v0.4·Evaluated 02 Nov 2026·OECD: 3.2 Clinical medicine·Subfield: Surgery·Basis: Full text·Type: Randomized controlled trial

Norepinephrine or phenylephrine for the prevention of post-spinal hypotension after caesarean section: A double-blinded, randomized, controlled study of fetal heart rate and fetal cardiac output

Lihong Sun et al.Lihong Sun, Yingying Tang, Feihe Guo et al.·2024·Journal of Clinical Anesthesia·10.1016/j.jclinane.2024.111533 ↗

Primary claim

Prophylactic infusion of comparable doses of phenylephrine or norepinephrine has similar effects on fetal heart rate and cardiac output changes after spinal anesthesia.

Tentative · superiority testing without equivalence margins cannot establish similarity despite no detected between-group differences
In brief

A blinded vasopressor trial adds direct fetal-circulation evidence in elective caesareans, but its null comparisons do not establish equivalence or absence of harm.

ReliabilityCaveats4 of 4 checks completeRead the 2 entries ↓
Fragile — the claim's weakest requirement is that the effect exists at all. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.
Abstract

STUDY OBJECTIVE: Spinal anesthesia often causes hypotension, with consequent risk to the fetus. The use of vasopressor agents has been highly recommended for the prevention of spinal anesthesia-induced hypotension during caesarean delivery. Many studies have shown that norepinephrine can provide more stable maternal hemodynamics than phenylephrine. We therefore tested the hypothesis that norepinephrine preserves fetal circulation better than phenylephrine when used to treat maternal hypotension consequent to spinal anesthesia. DESIGN: Prospective, randomized, double-blinded study. SETTING: Operating room. PATIENTS: We recruited 223 parturients with uncomplicated singleton pregnancies who were scheduled for elective caesarean section under combined spinal-epidural anesthesia. INTERVENTIONS: The patients received prophylactic intravenous infusion of either 0.08 μg/kg/min norepinephrine or 0.5 μg/kg/min phenylephrine for prevention of spinal anesthesia-induced hypotension. MEASUREMENTS: Changes in fetal heart rate and fetal cardiac output before and after spinal anesthesia were measured using noninvasive Doppler ultrasound. MAIN RESULTS: 90 subjects who received norepinephrine infusion and 93 subjects who received phenylephrine infusion were ultimately analyzed in the present study. The effects of norepinephrine and phenylephrine on the change of fetal heart rate and fetal cardiac output at 3 and 6 min after spinal block were similar. Although there was a statistically significant decrease in fetal cardiac output at 6 min after subarachnoid block initiation in both the norepinephrine group (mean difference 0.02 L/min; 95% CI, 0-0.04 L/min; P = 0.03) and the phenylephrine group (mean difference 0.02 L/min; 95% CI, 0-0.04 L/min; P = 0.02), it remained within the normal range. CONCLUSIONS: Prophylactic infusion of comparable doses of phenylephrine or norepinephrine has similar effects on fetal heart rate and cardiac output changes after spinal anesthesia. Neither phenylephrine nor norepinephrine has meaningful detrimental effects on fetal circulation or neonatal outcomes.

Key Claims

Primary finding · Tentative

Prophylactic infusion of comparable doses of phenylephrine or norepinephrine has similar effects on fetal heart rate and cardiac output changes after spinal anesthesia.

Fragile — the claim's weakest requirement is that the effect exists at all. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.

superiority testing without equivalence margins cannot establish similarity despite no detected between-group differences

Abstract; Conclusions; Highlights
Quote verified
Secondary · Tentative

there was a statistically significant decrease in fetal cardiac output in both groups.

within-group inference rests on single Doppler measurements and an unspecified paired testing approach

Results, paragraph 3; Table 3
Quote verified
Secondary · Tentative

Neither phenylephrine nor norepinephrine has meaningful detrimental effects on fetal circulation or neonatal outcomes.

short-term active-comparator testing without an unexposed control or powered clinical safety endpoints cannot exclude meaningful harm

Abstract; Conclusions; Highlights
Quote verified

Derived from the full evaluation — not a separate score.

Strengths · Limitations

Strengths

#methodological rigour

Randomised allocation with extensive personnel masking

An independent team member generated allocation, and an uninvolved assistant prepared study drugs. Patients, anaesthetists, the sonographer, and data collectors were blinded.

↳ Methods 2.2; Table 1

#contribution

Direct measurements extend fetal circulation evidence

Serial Doppler measurements address fetal heart rate and cardiac output directly, extending comparisons previously centred on maternal haemodynamics and neonatal blood gases.

↳ Introduction; Methods 2.4; Table 3

#methodological rigour

Systematic maternal and neonatal outcome reporting

The trial monitored maternal adverse events alongside fetal perfusion measures, umbilical blood gases, Apgar scores, and neonatal admission.

↳ Methods 2.4; Tables 2–4

Limitations

#methodological rigour

Null comparisons cannot establish clinical equivalence

The power calculation draws on maternal cardiac-output data rather than fetal-outcome variance. No equivalence margin or between-group confidence intervals establish that clinically meaningful differences are excluded.

↳ Methods 2.5; Table 3

#methodological rigour

Post-randomisation exclusions lack analytical sensitivity checks

Ten norepinephrine and seven phenylephrine participants were excluded after randomisation. Analysis of the remaining 90 and 93 participants lacks an intention-to-treat or sensitivity analysis.

↳ Results, participant flow paragraph

#reporting

Safety wording exceeds the comparative design

The conclusion of no meaningful fetal or neonatal detriment goes beyond a low-risk, short-term comparison without an unexposed control or adequately powered clinical safety outcomes.

↳ Abstract, Conclusions; Methods 2.1 and 2.5; Discussion, concluding paragraph

Does this match your read? Add your assessment ↓

Nabu Commentary

Independent allocation procedures, masking, objective Doppler measurements, and systematic harms reporting support the trial's execution. The direct fetal measurements add evidence beyond maternal-haemodynamic comparisons, but the maternal-derived power calculation and completer-only analysis limit interpretation of the null findings. Similarity and absence of meaningful harm require stronger inferential support than nonsignificant superiority tests provide. The Discussion identifies measurement and dosing limitations without sufficiently carrying their implications into the final conclusions.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
3.4±0.2

Contribution
3.5

Direct serial fetal Doppler measurements extend prior comparisons centred on maternal haemodynamics and neonatal acid–base outcomes. The advance remains bounded by the uncomplicated elective population and a null comparison that does not establish equivalence.

Introduction; Methods 2.4; Discussion, prior vasopressor studies
Methodological Rigour
3.3

Computer-generated allocation, independent drug preparation, masking, objective outcomes, and systematic adverse-event recording support the trial's execution. Completer-only analysis, a maternal-derived power justification, and absent equivalence margins introduce meaningful uncertainty about the null fetal comparison.

Methods 2.2–2.5; Results, participant flow; Tables 1–4
Reporting
3.4

The report's structure and tables make the comparison followable, but central similarity and no-detriment language communicates certainty beyond the design. Reporting slips in the bradycardia P value and cardiac-output definition also reduce precision.

Abstract, Conclusions; Methods 2.3; Results; Discussion, concluding paragraph
Positioning
3.4

The Discussion engages relevant maternal-haemodynamic, neonatal, and fetal-flow evidence and identifies important measurement and dosing limitations. Those limitations are not sufficiently carried through to the certainty of the concluding similarity and safety statements.

Discussion, prior-study comparisons, limitations paragraph, and concluding paragraph

Reliability

Caveats4 of 4 checks


Results checkNoted
  • there was a statistically significant decrease in fetal cardiac output in both groups: "norepinephrine group (mean difference 0.02 L/min; 95% CI, 0–0.04 L/min; P = 0.03)" (Abstract, Main results). The printed confidence interval has a zero lower limit alongside P = 0.03, but rounding could conceal a positive lower limit, so unrounded agreement cannot be determined. → Effect on result unclear
Reporting and transparencyNoted

The Methods contain a circular definition of cardiac output, without evidence that the numerical analysis used that definition. Ethics approval, prospective registration, and a conflict-of-interest declaration are reported.

Conflict of interest: declared · Ethics approval: declared · Preregistration: declared

Reference IntegrityClean

21 of 21 checkable references verified

21 references in manuscript

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 02 Nov 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Injuries and accidents · Adverse effects of medical treatment
Type of advanceEmpirical
Route to useNamed
AdvanceExtends
BeneficiariesMedium
CitationsFWCI 8.8
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessPiloted
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

A single-centre randomised double-blind trial in 183 analysed parturients is the only direct test of this fetal-circulation comparison, without independent confirmation elsewhere.

From the paper
“The results can provide certain references for practitioners to choose vasoactive drugs in obstetric anesthesia.”

The paper names anaesthetic practitioners as the actors who would use its results to select vasopressors in obstetric anesthesia.

Pathway

Obstetric anaesthetists could use either prophylactic norepinephrine or phenylephrine for spinal-induced hypotension at caesarean section, reassured that fetal heart rate and cardiac output are similarly unaffected.

Barrier

Evidence covers only uncomplicated pregnancies at fixed doses in one centre, leaving uncertain effects in high-risk fetuses, preeclampsia or cardiovascular disease.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. A Quantitative, Systematic Review of Randomized Controlled Trials of Ephedrine Versus Phenylephrine for the Management of Hypotension During Spinal Anesthesia for Cesarean Delivery

    Anna Lee, Warwick D. Ngan Kee, Tony Gin · 2002 · Basic medicine

    Primary claim

    Women given phenylephrine had neonates with higher umbilical arterial pH values than those given ephedrine

    Supported
    Evidence Score
    3.8±0.1
    Reliability
    Caveats
  2. RNA-Based Therapies for Lipoprotein(a) Reduction: Antisense Oligonucleotides, Small Interfering RNAs, and Emerging Platforms

    Parcha, Bittner · 2026 · Clinical medicine

    Primary claim

    Phase 2 data demonstrate Lp(a) reductions ranging from 79% to approximately 97% on a placebo-adjusted basis, approaching the practical limit of apo(a) suppression, with favorable short-term safety profiles.

    Supported
    Evidence Score
    3.7±0.2
    Reliability
    Caveats
  3. From pigs to people: what is it like to perform a pig-to-human kidney xenotransplant?

    Daniel Rodger, Jonathan A Smith · 2026 · Clinical medicine

    Primary claim

    if xenotransplantation does 1 day demonstrate safety and efficacy in clinical trials, this account suggests that, at the level of surgical experience, performing a xenotransplant may feel minimally different from an allotransplant

    Tentative
    Evidence Score
    3.3±0.2
    Reliability
    Caveats

How the rubric works →